Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
451 Leser
Artikel bewerten:
(2)

Q-linea installs the first ASTar system at Uppsala University Hospital

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ --Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate in the company's European pivotal clinical study.

Following this spring's collaboration with the laboratory for clinical microbiology at Uppsala University Hospital, Q-linea has now installed an ASTar instrument for evaluation at the hospital for the upcoming pivotal clinical study.

"It is an important step for us that ASTar now will be evaluated in a real laboratory environment by a potential customer. Uppsala University Hospital is precisely the type of larger hospital for which ASTar is designed. Our collaboration during the spring and summer has worked excellently and we are very happy that they will participate in the upcoming study. The interest in testing ASTar has been great from several hospitals and it feels really positive that Uppsala University Hospital will be the first hospital to evaluate ASTar.", said Jonas Jarvius, CEO of Q-linea.

Q-linea plans to begin the prospective performance study, with 80 to 100 patients, in the fall of 2020. The results of the study will be part of the documentation in the ongoing process for CE-IVD approval prior to the market launch of ASTar. The study will be conducted internally at Q-linea, at Uppsala University Hospital and at one to two additional sites.

For more information, please contact:
Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com,
+46 (0)70-323 77 60

Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0)70-600 15 20

The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on September 4, 2020.

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/q-linea/r/q-linea-installs-the-first-astar-system-at-uppsala-university-hospital,c3188721

The following files are available for download:

https://mb.cision.com/Main/17731/3188721/1302296.pdf

Press release (PDF)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.